Intestinal inflammation impaires epithelial insulin signaling pathway which in turn triggers glycolipid intake disorder [7, 8], accumulates excessive amounts of glucose and free fatty acids(FFA)in the circulation and exacerbates systemic insulin resistance [9–11].Consequently, intestinal immune system may be a novel therapeutic target in the treatment of insulin resistance. Here, INS is linked to Insulin resistance.